Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs.).
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of DirectorsSAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024.
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking TherapiesPALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally develop into red blood cells, white blood cells, and platelets. In AML, these abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells. According to Global Market Insights the Acute Myeloid Leukemia Market was valued at USD 2.1 Billion in 2023 and is estimated to grow at a CAGR of 10.7% between 2024 and 2032. High market growth can be attributed to factors such as advancement in research and technology, surging government initiatives and policies, early diagnosis coupled with efforts to implement screening programs. Also, increasing prevalence of acute myeloid leukemia (AML) is a significant factor driving the growth of the market. The report said: “For instance, according to the American Cancer Society, in 2023, there were about 20,380 new cases of acute myeloid leukemia (AML) in the U.S. alone. Hence, as the population ages, the incidence of AML tends to rise, contributing to a larger patient pool seeking diagnosis and treatment, thereby fostering the market growth. Surging government initiatives and polices play a pivotal role in driving the acute myeloid leukemia industry. Also, increased government funding for medical research, including acute myeloid leukemia research, drive advancements in understanding the molecular basis of AML, leading to the development of innovative therapies and treatment modalities.” Active biotech and pharma companies in the markets this week include Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), Syndax Pharmaceuticals (
NASDAQSNDX), Kura Oncology, Inc.
NASDAQ: KURANASDAQKURA)
(NASDAQ: BMEANASDAQBMEA
, Johnson & Johnson (NYSE: JNJNYSE
).
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. MetzgerBOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015.
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced the full results from the pivotal Phase 2 AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with refractory chronic graft-versus-host disease (GVHD) who had received at least two prior lines of systemic therapy. These data are featured today in the Plenary Scientific Session (Abstract #1) at the 65th American Society of Hematology Annual Meeting 2023 (ASH 2023), held December 9-12, 2023, in San Diego and virtually.
